A pilot controlled clinical trial of ABT-418, a cholinergic agonist, in the treatment of adults with attention deficit hyperactivity disorder

American Journal of Psychiatry

Volumn 156, Issue 12, 1999, Pages 1931-1937

  Wilens, Timothy E ^a   Biederman, Joseph ^a   Spencer, Thomas J ^a   Bostic, Jeff ^a   Prince, Jefferson ^a   Monuteaux, Michael C ^a   Soriano, Jennifer ^a   Fine, Catherine ^a   Abrams, Annah ^a   Rater, Michael ^a   Polisner, David ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3 METHYL 5 (1 METHYL 2 PYRROLIDINYL)ISOXAZOLE; CHOLINERGIC RECEPTOR STIMULATING AGENT;

ADULT; ARTICLE; ATTENTION DEFICIT DISORDER; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HUMAN; MALE; NAUSEA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TRANSDERMAL DRUG ADMINISTRATION; VERTIGO;

ADMINISTRATION, CUTANEOUS; ADULT; AGE FACTORS; ANTI-ANXIETY AGENTS; ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY; CHOLINERGIC AGONISTS; CROSS-OVER STUDIES; DIZZINESS; DOUBLE-BLIND METHOD; FEMALE; HUMANS; ISOXAZOLES; MALE; NAUSEA; PILOT PROJECTS; PYRROLIDINES; TREATMENT OUTCOME;

EID: 0032726966     PISSN: 0002953X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (56)

1. Bauermeister JJ, Canino G, Bird H: Epidemiology of disruptive behavior disorders, in Child and Adolescent Psychiatric Clinics of North America, vol 3. Edited by Greenhill L. Philadelphia, WB Saunders, 1994, pp 177-194
2. Murphy K, Barkley RA: Prevalence of DSM-IV symptoms of ADHD in adult licensed drivers: implications for clinical diagnosis. J Attention Disorders 1996; 1:147-161
3. Weiss G, Hechtman LT: Hyperactive Children Grown Up. New York, Guilford Press, 1986
4. Mannuzza S, Klein RG, Bessler A, Malloy P, LaPadula M: Adult outcome of hyperactive boys: educational achievement, occupational rank, and psychiatric status. Arch Gen Psychiatry 1993; 50:565-576
5. Biederman J, Faraone S, Milberger S, Curtis S, Chen L, Marrs A, Ouellette C, Moore P, Spencer T: Predictors of persistence and remission of ADHD into adolescence: results from a four-year prospective follow-up study. J Am Acad Child Adolesc Psychiatry 1996; 35:343-351
6. Fisher M: Persistence of ADHD into adulthood: it depends on whom you ask. ADHD Report 1997; 5(May):8-10
7. Millstein R, Wilens T, Biederman J, Spencer T: Presenting symptoms of ADHD in clinically referred adults with ADHD. J Attention Disorders 1997; 2:159-166
8. Biederman J, Faraone SV, Spencer T, Wilens TE, Norman D, Lapey KA, Mick E, Lehman BK, Doyle A: Patterns of psychiatric comorbidity, cognition, and psychosocial functioning in adults with attention deficit hyperactivity disorder. Am J Psychiatry 1993; 150:1792-1798
9. Shekim WO, Asarnow RF, Hess E, Zaucha K, Wheeler N: A clinical and demographic profile of a sample of adults with attention deficit hyperactivity disorder, residual state. Compr Psychiatry 1990; 31:416-425
10. Zametkin A, Liotta W: The neurobiology of attention-deficit/hyperactivity disorder. J Clin Psychiatry 1998; 59:17-23
11. Milberger S, Biederman J, Faraone S, Chen L, Jones J: ADHD is associated with early initiation of cigarette smoking in children and adolescents. J Am Acad Child Adolesc Psychiatry 1997; 36:37-43
12. Pomerleau O, Downey K, Stelson F, Pomerleau C: Cigarette smoking in adult patients diagnosed with ADHD. J Subst Abuse 1996; 7:373-378
13. Milberger S, Biederman J, Faraone SV, Chen L, Jones J: Is maternal smoking during pregnancy a risk factor for attention deficit hyperactivity disorder in children? Am J Psychiatry 1996; 153:1138-1142
14. Fung YK, Lau Y-S: Effects of prenatal nicotine exposure on rat striatal dopaminergic and nicotinic systems. Pharmacol Biochem Behav 1989; 33:1-6
15. Johns JM, Louis TM, Becker RF, Means LW: Behavioral effects of prenatal exposure to nicotine in guinea pigs. Neurobehav Toxicol Teratol 1982; 4:365-369
16. Mereu G, Yoon K, Gessa G, Naes L, Westfall T: Preferential stimulation of ventral tegmental area dopaminergic neurons by nicotine. Eur J Pharmacol 1987; 141:395-399
17. Westfall T, Grant H, Perry H: Release of dopamine and 5-hydroxytryptamine from rat striatal slices following activation of nicotinic cholinergic receptors. Gen Pharmacol 1983; 14:321-325
18. Levin E, Conners C, Sparrow E, Hinton S, Erhardt D, Meck W, Rose J, March J: Nicotine effects on adults with attention-deficit/hyperactivity disorder. Psychopharmacology (Berl) 1996; 123:55-63
19. Arneric SP, Sullivan JP, Briggs CA, Donnelly-Roberts D, Anderson DJ, Raszkiewicz JL, Hughes ML, Cadman ED, Adams P, Garvey DS, Wasicak J, Williams M: (S)-3-Methyl-5-(1-methyl-2-pyrrolidinyl) isoxazole (ABT 418): a novel cholinergic ligand with cognition-enhancing and anxiolytic activities, I: in vitro characterization. J Pharmacol Exp Ther 1994; 270:310-318
20. Decker MW, Brioni JD, Sullivan JP, Buckley MJ, Raszkiewicz JL, Kang CH, Kim DJ, Giardina W, Wasicak JT, Radek R, Williams M, Arneric SP: (S)-3-Methyl-5-(1-methyl-2-pyrrolidinyl)isoxazole (ABT 418): a novel cholinergic ligand with cognition-enhancing and anxiolytic activities, II: in vitro characterization. J Pharmacol Exp Ther 1994; 270:319-328
21. Benowitz NL: Pharmacology of nicotine, in Handbook of Substance Abuse: Neurobehavioral Pharmacology. Edited by Tarter RE, Ammerman RT, Ott P. New York, Plenum, 1998, pp 293-297
22. Arneric SP, Anderson DJ, Bannon AW, Briggs CA, Buccafusco JJ, Brioni JD, Cannon JB, Decker MW, Donnelly-Roberts D, Gopalakrishnan M, Holladay MW, Kyncl J, Marsh KC, Pauly J, Radek RJ, Rodrigues AD, Sullivan JP: Preclinical pharmacology of ABT-418: a prototypical cholinergic channel activator for the potential treatment of Alzheimer's disease. CNS Drug Reviews 1995; 1:1-26
23. Meck W, Church R: Cholinergic modulation of the content of temporal memory. Behav Neurosci 1987; 101:457-464
24. Peeke S, Peeke H: Attention, memory, and cigarette smoking. Psychopharmacology (Berl) 1984; 84:205-216
25. Jones G, Sahakian B, Levy R, Warburton D, Gyra J: Effects of acute subcutaneous nicotine on attention, information and short-term memory in Alzheimer's disease. Psychopharmacology (Berl) 1992; 108:485-494
26. Wesnes K, Warburton D: The effects of cigarettes of varying yield on rapid information processing performance. Psychopharmacology (Berl) 1984; 82:338-342
27. Parrott AC, Winder G: Nicotine chewing gum (2 mg, 4 mg) and cigarette smoking: comparative effects upon vigilance and heart rate. Psychopharmacology (Berl) 1989; 97:257-261
28. Orvaschel H: Psychiatric interviews suitable for use in research with children and adolescents. Psychopharmacol Bull 1985; 21:737-745
29. Hollingshead AB: Four-Factor Index of Social Status. New Haven, Conn, Yale University, Department of Sociology, 1975
30. Spencer T, Wilens TE, Biederman J, Faraone SV, Ablon S, Lapey K: A double blind, crossover comparison of methylphenidate and placebo in adults with childhood onset attention deficit hyperactivity disorder. Arch Gen Psychiatry 1995; 52:434-443
31. Wilens TE, Biederman J, Prince J, Spencer TJ, Faraone SV, Warburton R, Schleifer D, Harding M, Linehan C, Geller D: Six-week, double-blind, placebo-controlled study of desipramine for adult attention deficit hyperactivity disorder. Am J Psychiatry 1996; 153:1147-1153
32. NIMH: Clinical Global Impressions (CGI) scale. Psychopharmacol Bull 1985; 21:839-843
33. Barkley RA: Attention Deficit Hyperactivity Disorder: A Handbook for Diagnosis and Treatment. New York, Guilford Press, 1990
34. DuPaul G: The ADHD Rating Scale: Normative Data, Reliability, and Validity. Worcester, University of Massachusetts Medical School, 1990
35. Barkley RA, Biederman J: Towards a broader definition of the age-of-onset criterion for attention-deficit hyperactivity disorder. J Am Acad Child Adolesc Psychiatry 1997; 36:1204-1210
36. Murphy K, Barkley RA: Preliminary normative data on DSMIV criteria for adults. ADHD Report 1995; 3(3):6-7
37. Wilens TE, Biederman J, Spencer TJ, Frazier J, Prince J, Bostic J, Rater M, Soriano J, Hatch M, Sienna M, Millstein RB, Abrantes A: Controlled trial of high doses of pemoline for adults with attention-deficiVhyperactivity disorder. J Clin Psychopharmacol 1999; 19:257-264
38. Hamilton M: A rating scale for depression. J Neurol Neurosurg Psychiatry 1960; 23:56-62
39. Beck AT, Ward CH, Mendelson M, Mock J, Erbaugh J: An inventory for measuring depression. Arch Gen Psychiatry 1961; 4:561-571
40. Hamilton M: The assessment of anxiety states by rating. Br J Med Psychol 1959; 32:50-55
41. Spencer T, Biederman J, Wilens T, Prince J, Hatch M, Jones J, Harding M, Faraone SV, Seidman L: Effectiveness and tolerability of tomoxetine in adults with attention deficit hyperactivity disorder. Am J Psychiatry 1998; 155:693-695
42. Gibbons RD, Hedeker D, Elkin I, Waternaux C, Kraemer HC, Greenhouse JB, Shea T, Imber SD, Sotsky SM, Watkins JT: Some conceptual and statistical issues in analysis of longitudinal psychiatric data. Arch Gen Psychiatry 1993; 50:739-750
43. Bailor JC, Mosteller F: Medical Uses of Statistics. Waltham, Mass, New England Journal of Medicine Books, 1986
44. Levin E: Nicotinic systems and cognitive function. Psychopharmacology (Berl) 1992; 108:417-431
45. Wesnes K, Warburton DM: Smoking, nicotine, and human performance. Pharmacol Ther 1983; 21:189-208
46. Marks MJ, Grady SR, Collins AC: Downregulation of nicotinic receptor function after chronic nicotine infusion. J Pharmacol Exp Ther 1993; 266:1268-1276
47. Levin ED, Rosecrans JA: Promise of nicotinic-based therapeutic treatments. Drug Dev Res 1994; 31:1-2
48. Sallee FR, Stiller RL, Perel JM: Pharmacodynamics of pemoline in attention deficit disorder with hyperactivity. J Am Acad Child Adolesc Psychiatry 1992; 31:244-251
49. Hart EL, Lahey BB, Loeber R, Applegate B, Frick PJ: Developmental change in attention-deficit hyperactivity disorder in boys: a four-year longitudinal study. J Abnorm Child Psychol 1995; 23:729-749
50. Henningfield JE: Behavioral pharmacology of cigarette smoking. Advances in Behavioral Pharmacol 1984; 4:131-210
51. Pickworth WB, Bunker E, Henningfield J: Transdermal nicotine: reduction of smoking with minimal abuse liability. Psychopharmacology (Berl) 1994; 115:9-14
52. Shih T, Khachaturian Z, Barry H III, Hanin I: Cholinergic mediation of the inhibitory effect of methylphenidate on neuronal activity in the reticular formation. Neuropharmacology 1976; 15:55-60
53. Findling RL, Schwartz MA, Flannery DJ, Manos MJ: Venlafaxine in adults with attention-deficit /hyperactivity disorder: an open clinical trial. J Clin Psychiatry 1995; 57:184-189
54. Ward MF, Wender PH, Reimherr FW: The Wender Utah Rating Scale: an aid in the retrospective diagnosis of childhood attention deficit hyperactivity disorder. Am J Psychiatry 1993; 150:885-890
55. Stein MA, Sandoval R, Szumowski E, Roizen N, Reinecke MA, Blondis TA, Klein Z: Psychometric characteristics of the Wender Utah Rating Scale: reliability and factor structure for mer and women. Psychopharmacol Bull 1995; 31:423-431
56. Spencer T, Biederman J, Wilens TE, Faraone SV: Adults with attention-deficit/hyperactivity disorder: a controversial diagnosis. J Clin Psychiatry 1998; 59(suppl 7):59-68